{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:27:46Z","timestamp":1792585666310,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272811"],"award-info":[{"award-number":["82272811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer in the real world.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The retrospective analysis was conducted on the clinical records of 402 patients with advanced gastric cancer who were admitted to the Nanjing Drum Tower Hospital between December 2017 and April 2022 and who had received immunotherapy. Observation target: drug use, treatment, adverse reaction type and grade, objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>By retrospectively analyzing the data of patients with advanced gastric cancer treated with ICIs previously admitted to our medical center, we found some clinical characteristic factors associated with the occurrence of irAEs as well as the efficacy and prognosis: the presence or absence of hypertension, whether or not to receive targeted therapies can predict the occurrence of immune-related adverse events (irAEs), and the more the presence of irAEs, the better the prognosis. These can help clinicians in clinical drug selection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this paper show that the occurrence of irAEs is associated with patients\u2019 OS. irAEs occurrence can prolong patients\u2019 OS. irAEs occurrence may serve as a surrogate marker for ICIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-024-05703-8","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:02:05Z","timestamp":1712556125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world"],"prefix":"10.1007","volume":"150","author":[{"given":"Wen","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"10125","key":"5703_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nik\u0161i\u0107 M, Bonaventure A, Valkov M, Johnson CJ, Est\u00e8ve J, Ogunbiyi OJ, Azevedo ESG, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP (2018) Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391(10125):1023\u20131075. https:\/\/doi.org\/10.1016\/s0140-6736(17)33326-3","journal-title":"Lancet"},{"issue":"5","key":"5703_CR2","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/circresaha.116.308445","volume":"119","author":"AR Cameron","year":"2016","unstructured":"Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, Beall C, McNeilly AD, Balfour DJ, Savinko T, Wong AK, Viollet B, Sakamoto K, Fagerholm SC, Foretz M, Lang CC, Rena G (2016) Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res 119(5):652\u2013665. https:\/\/doi.org\/10.1161\/circresaha.116.308445","journal-title":"Circ Res"},{"issue":"22","key":"5703_CR3","doi-asserted-by":"publisher","first-page":"10674","DOI":"10.1073\/pnas.1819889116","volume":"116","author":"VP Chauhan","year":"2019","unstructured":"Chauhan VP, Chen IX, Tong R, Ng MR, Martin JD, Naxerova K, Wu MW, Huang P, Boucher Y, Kohane DS, Langer R, Jain RK (2019) Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy. Proc Natl Acad Sci USA 116(22):10674\u201310680. https:\/\/doi.org\/10.1073\/pnas.1819889116","journal-title":"Proc Natl Acad Sci USA"},{"key":"5703_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107498","volume":"95","author":"C Chen","year":"2021","unstructured":"Chen C, Wu B, Zhang C, Xu T (2021) Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol 95:107498. https:\/\/doi.org\/10.1016\/j.intimp.2021.107498","journal-title":"Int Immunopharmacol"},{"key":"5703_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A (2022) Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol 13:779691. https:\/\/doi.org\/10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"key":"5703_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","volume":"145","author":"FG Dall'Olio","year":"2020","unstructured":"Dall\u2019Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A (2020) ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2014a systematic review and meta-analysis of real world data. Lung Cancer 145:95\u2013104. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.027","journal-title":"Lung Cancer"},{"key":"5703_CR7","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3389\/fimmu.2020.01582","volume":"11","author":"G Daryabor","year":"2020","unstructured":"Daryabor G, Atashzar MR, Kabelitz D, Meri S, Kalantar K (2020) The effects of type 2 diabetes mellitus on organ metabolism and the immune system. Front Immunol 11:1582. https:\/\/doi.org\/10.3389\/fimmu.2020.01582","journal-title":"Front Immunol"},{"issue":"8","key":"5703_CR8","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.3748\/wjg.v22.i8.2403","volume":"22","author":"A Digklia","year":"2016","unstructured":"Digklia A, Wagner AD (2016) Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol 22(8):2403\u20132414. https:\/\/doi.org\/10.3748\/wjg.v22.i8.2403","journal-title":"World J Gastroenterol"},{"issue":"2","key":"5703_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"1","key":"5703_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE\u2014version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliograficas 112(1):90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermo-Sifiliograficas"},{"issue":"10","key":"5703_CR11","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"issue":"10","key":"5703_CR12","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1084\/jem.20070657","volume":"204","author":"TJ Guzik","year":"2007","unstructured":"Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204(10):2449\u20132460. https:\/\/doi.org\/10.1084\/jem.20070657","journal-title":"J Exp Med"},{"issue":"11","key":"5703_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1231292","volume":"5","author":"O Hasan Ali","year":"2016","unstructured":"Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Fr\u00fch M, Flatz L (2016) Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 5(11):e1231292. https:\/\/doi.org\/10.1080\/2162402x.2016.1231292","journal-title":"Oncoimmunology"},{"key":"5703_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014a systematic review and meta-analysis. Cancer Treat Rev 92:102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134","journal-title":"Cancer Treat Rev"},{"issue":"28","key":"5703_CR15","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/jco.2017.76.6212","volume":"36","author":"YY Janjigian","year":"2018","unstructured":"Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36(28):2836\u20132844. https:\/\/doi.org\/10.1200\/jco.2017.76.6212","journal-title":"J Clin Oncol"},{"issue":"10294","key":"5703_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2","journal-title":"Lancet"},{"issue":"1","key":"5703_CR17","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1186\/s12885-020-07251-z","volume":"20","author":"H Jiang","year":"2020","unstructured":"Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N (2020) Safety and efficacy of sintilimab combined with oxaliplatin\/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer 20(1):760. https:\/\/doi.org\/10.1186\/s12885-020-07251-z","journal-title":"BMC Cancer"},{"issue":"2","key":"5703_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(2):234\u2013247. https:\/\/doi.org\/10.1016\/s1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"issue":"1","key":"5703_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/jjco\/hyaa202","volume":"51","author":"A Kawazoe","year":"2021","unstructured":"Kawazoe A, Shitara K, Boku N, Yoshikawa T, Terashima M (2021) Current status of immunotherapy for advanced gastric cancer. Jpn J Clin Oncol 51(1):20\u201327. https:\/\/doi.org\/10.1093\/jjco\/hyaa202","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"5703_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41571-021-00594-x","volume":"19","author":"D Killock","year":"2022","unstructured":"Killock D (2022) Pembrolizumab for HER2(+) gastric cancer. Nat Rev Clin Oncol 19(3):150. https:\/\/doi.org\/10.1038\/s41571-021-00594-x","journal-title":"Nat Rev Clin Oncol"},{"issue":"424","key":"5703_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","volume":"10","author":"Y Lan","year":"2018","unstructured":"Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hern\u00e1ndez VM, Jenkins MH, Fontana RE, Deshpande A, Locke G, Sabzevari H, Radvanyi L, Lo KM (2018) Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci Transl Med 10(424):eaan5488. https:\/\/doi.org\/10.1126\/scitranslmed.aan5488","journal-title":"Sci Transl Med"},{"issue":"1","key":"5703_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.Ccr-21-1193","volume":"28","author":"JC Lee","year":"2022","unstructured":"Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI (2022) The liver-immunity nexus and cancer immunotherapy. Clin Cancer Res 28(1):5\u201312. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1193","journal-title":"Clin Cancer Res"},{"issue":"17","key":"5703_CR23","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P (2019) Immune checkpoint inhibitors: basics and challenges. Curr Med Chem 26(17):3009\u20133025. https:\/\/doi.org\/10.2174\/0929867324666170804143706","journal-title":"Curr Med Chem"},{"issue":"7","key":"5703_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268244","volume":"17","author":"Y Li","year":"2022","unstructured":"Li Y, Amaladas N, O\u2019Mahony M, Manro JR, Inigo I, Li Q, Rasmussen ER, Brahmachary M, Doman TN, Hall G, Kalos M, Novosiadly R, Puig O, Pytowski B, Schaer DA (2022) Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models. PLoS ONE 17(7):e0268244. https:\/\/doi.org\/10.1371\/journal.pone.0268244","journal-title":"PLoS ONE"},{"key":"5703_CR25","doi-asserted-by":"publisher","first-page":"S1191","DOI":"10.1016\/j.annonc.2020.08.2296","volume":"31","author":"M Moehler","year":"2020","unstructured":"Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Poulart V, Cullen D, Lei M, Kondo K, Li M, Ajani JA, Janjigian YY (2020) LBA6_PR nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann Oncol 31:S1191. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2296","journal-title":"Ann Oncol"},{"issue":"3","key":"5703_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s12029-023-00920-9","volume":"54","author":"K Muro","year":"2023","unstructured":"Muro K, Shitara K, Yamaguchi K, Yoshikawa T, Satake H, Hara H, Sugimoto N, Machida N, Goto M, Kawakami H, Amagai K, Omuro Y, Esaki T, Hironaka S, Nishina T, Komatsu Y, Matsubara H, Shiratori S, Han S, Satoh T, Ohtsu A (2023) Efficacy of pembrolizumab monotherapy in japanese patients with advanced gastric or gastroesophageal junction cancer. J Gastrointest Cancer 54(3):951\u2013961. https:\/\/doi.org\/10.1007\/s12029-023-00920-9","journal-title":"J Gastrointest Cancer"},{"issue":"1","key":"5703_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","volume":"16","author":"M Niu","year":"2023","unstructured":"Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, Zeng L, Shi J, Zhang J, Zhou P, Zhang T, Mei Q, Chu Q, Wu K (2023) Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol 16(1):94. https:\/\/doi.org\/10.1186\/s13045-023-01487-5","journal-title":"J Hematol Oncol"},{"issue":"6","key":"5703_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH (2019) Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol 40(6):511\u2013523. https:\/\/doi.org\/10.1016\/j.it.2019.04.002","journal-title":"Trends Immunol"},{"issue":"2","key":"5703_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"5","key":"5703_CR30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","volume":"30","author":"AJ Schoenfeld","year":"2019","unstructured":"Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD (2019) Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 30(5):839\u2013844. https:\/\/doi.org\/10.1093\/annonc\/mdz077","journal-title":"Ann Oncol"},{"issue":"1\u20133","key":"5703_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12026-014-8548-6","volume":"59","author":"MV Singh","year":"2014","unstructured":"Singh MV, Chapleau MW, Harwani SC, Abboud FM (2014) The immune system and hypertension. Immunol Res 59(1\u20133):243\u2013253. https:\/\/doi.org\/10.1007\/s12026-014-8548-6","journal-title":"Immunol Res"},{"issue":"10251","key":"5703_CR32","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/s0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet 396(10251):635\u2013648. https:\/\/doi.org\/10.1016\/s0140-6736(20)31288-5","journal-title":"Lancet"},{"issue":"6","key":"5703_CR33","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.Ccr-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Mart\u00e9 JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL (2018) Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2. Adv Solid Tumors Clin Cancer Res 24(6):1287\u20131295. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2653","journal-title":"Adv Solid Tumors Clin Cancer Res"},{"key":"5703_CR34","doi-asserted-by":"publisher","first-page":"5035261","DOI":"10.1155\/2019\/5035261","volume":"2019","author":"P Sun","year":"2019","unstructured":"Sun P, Jin Q, Nie S, Jia S, Li Y, Li X, Guo F (2019) Unlike PD-L1, PD-1 is downregulated on partial immune cells in type 2 diabetes. J Diabetes Res 2019:5035261. https:\/\/doi.org\/10.1155\/2019\/5035261","journal-title":"J Diabetes Res"},{"issue":"3","key":"5703_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5703_CR36","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1158\/1538-7445.AM2015-2857","volume":"75","author":"P Tumeh","year":"2015","unstructured":"Tumeh P, Rosenblum M, Handley N, Tsai K, Sanchez Rodriguez R, Khurana N, Harview C, Spasic M, Sanchez P, Chang J, Shintaku I, Taylor E, Chmielowski B, Grogan T, Elashoff D, Pierce R, Daud A (2015) Abstract 2857: metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma. Cancer Res 75:2857. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-2857","journal-title":"Cancer Res"},{"issue":"12","key":"5703_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"1","key":"5703_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, Qu XJ, Qiu H, Zhang YJ, Ying JE, Zhang J, Sun LY, Lin RB, Wang C, Liu H, Qiu MZ, Guan WL, Rao SX, Ji JF, Xin Y, Sheng WQ, Xu HM, Zhou ZW, Zhou AP, Jin J, Yuan XL, Bi F, Liu TS, Liang H, Zhang YQ, Li GX, Liang J, Liu BR, Shen L, Li J, Xu RH (2024) The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun 44(1):127\u2013172. https:\/\/doi.org\/10.1002\/cac2.12516","journal-title":"Cancer Commun"},{"key":"5703_CR39","doi-asserted-by":"publisher","first-page":"S1331","DOI":"10.1016\/j.annonc.2021.08.2133","volume":"32","author":"J Xu","year":"2021","unstructured":"Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Guo Y, Li Z, Liu Y, Wang Y, Zhou H (2021) LBA53 sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann Oncol 32:S1331. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2133","journal-title":"Ann Oncol"},{"issue":"1","key":"5703_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, Luo S, Zhou P, Wu K (2021) The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J Hematol Oncol 14(1):27. https:\/\/doi.org\/10.1186\/s13045-021-01045-x","journal-title":"J Hematol Oncol"},{"issue":"12","key":"5703_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005543","volume":"10","author":"M Yi","year":"2022","unstructured":"Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, Zhou P, Dai Z, Wu K (2022) Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer 10(12):e005543. https:\/\/doi.org\/10.1136\/jitc-2022-005543","journal-title":"J Immunother Cancer"},{"key":"5703_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627089","volume":"8","author":"X Yu","year":"2021","unstructured":"Yu X, Zhang X, Yao T, Zhang Y, Zhang Y (2021) Fatal adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Front Med 8:627089. https:\/\/doi.org\/10.3389\/fmed.2021.627089","journal-title":"Front Med"},{"issue":"1","key":"5703_CR43","doi-asserted-by":"publisher","first-page":"20038","DOI":"10.1038\/s41598-022-24286-3","volume":"12","author":"F Zhao","year":"2022","unstructured":"Zhao F, Zhu J, Yu R, Shao T, Chen S, Zhang G, Shu Q (2022) Cutaneous adverse events in patients treated with PD-1\/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis. Sci Rep 12(1):20038. https:\/\/doi.org\/10.1038\/s41598-022-24286-3","journal-title":"Sci Rep"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05703-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05703-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:04:47Z","timestamp":1716422687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05703-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5703"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05703-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3903020\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the Ethic Committee of the Nanjing Drum Tower Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"180"}}